Prostatic artery embolization (PAE) for the treatment of benign prostatic syndrome: medium-term effect of therapy

被引：0
作者：
Müllhaupt G. [1 ]
Abt D. [1 ,2 ]
Hechelhammer L. [3 ]
Schmid H.-P. [1 ]
机构：
[1] Klinik für Urologie, Institut für Medizin, Universität St. Gallen, St. Gallen
[2] Klinik für Urologie, Spitalzentrum Biel/Centre hospitalier Bienne, Bienne
[3] Klinik für Radiologie und Nuklearmedizin, Institut für Medizin, Universität St. Gallen, St. Gallen
来源：
Journal für Urologie und Urogynäkologie/Österreich | 2022年 / 29卷 / 1期
关键词：
Benign prostatic hyperplasia; Efficacy; Embolization of the prostate; Lower urinary tract symptoms; Minimally invasive treatment; Randomized trial; Safety; Transurethral surgery;
D O I：
10.1007/s41972-021-00151-9
中图分类号：
学科分类号：
摘要：
Benign prostatic hyperplasia represents one of the most common diseases in men and is often associated with lower urinary tract symptoms due to the prostatic obstruction (LUTS/BPO), with more than 50% of men already affected by the age of 60. If benign prostatic syndrome (BPS) does not respond adequately to drug therapy, surgical intervention is recommended. Due to the morbidity of surgical methods, a number of minimally invasive procedures have been developed, including prostatic artery embolization (PAE). To date, a lack of reliable medium- to long-term follow-up data has been raised as a major disadvantage of PAE. In a randomized controlled trial performed in St. Gallen, Switzerland, the authors showed that a reduction in LUTS/BPO can be detected even 24 months after PAE and that PAE is associated with significantly fewer adverse events compared to transurethral resection of the prostate (TURP). However, improvements in patient-reported outcomes and functional parameters are more pronounced after TURP. PAE is therefore not a definitive treatment for a relevant proportion of patients. This should be considered in patient selection and counseling. In summary, PAE represents an option for men seeking minimally invasive treatment and accepting outcomes inferior to those of more invasive surgical treatments. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, ein Teil von Springer Nature.
引用
收藏
页码：1 / 5
页数：4
相关论文
共 19 条
  • [1] Berry S.J., Coffey D.S., Walsh P.C., Et al., The development of human benign prostatic hyperplasia with age, J Urol, 132, pp. 474-479, (1984)
  • [2] Parsons J.K., Wilt T.J., Wang P.Y., Et al., Progression of lower urinary tract symptoms in older men: a community based study, J Urol, 183, pp. 1915-1920, (2010)
  • [3] Foster H.E., Dahm P., Kohler T.S., Et al., Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: aUA guideline amendment 2019, J Urol, 202, pp. 592-598, (2019)
  • [4] Gravas S., Cornu J.N., Gacci M., Et al., 2020 European guidelines on the „management of non-neurogenic male LUTS“, (2020)
  • [5] Cornu J.N., Ahyai S., Bachmann A., Et al., A systematic review and meta-analysis of functional outcomes and complications following trans- urethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update, Eur Urol, 67, pp. 1066-1096, (2015)
  • [6] Reich O., Gratzke C., Bachmann A., Et al., Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients, J Urol, 180, pp. 246-249, (2008)
  • [7] Abt D., Hechelhammer L., Mullhaupt G., Et al., Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial, BMJ, 361, (2018)
  • [8] Abt D., Mullhaupt G., Hechelhammer L., Et al., Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial, Eur Urol, 80, pp. 34-42, (2021)
  • [9] Abt D., Mullhaupt G., Mordasini L., Et al., Outcome prediction of prostatic artery embolization: post hoc analysis of a randomized, open-label, non-inferiority trial, BJU Int, 124, pp. 134-144, (2019)
  • [10] Zumstein V., Betschart P., Vetterlein M.W., Et al., Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis, Eur Urol Focus, 5, pp. 1091-1100, (2019)
12